Format

Send to

Choose Destination
See comment in PubMed Commons below
JCI Insight. 2016 Dec 22;1(21):e88955. doi: 10.1172/jci.insight.88955.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Author information

1
Department of Medicine.
2
Department of Pediatrics.
3
Program for Computational Biology and Bioinformatics,; Department of Pathology.
4
Department of Pathology.
5
Department of Surgery.
6
Department of Medicine,; Yale Cancer Center.
7
Yale Center for Analytic Sciences.
8
Department of Dermatology.
9
Department of Medicine,; Yale Cancer Center,; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
10
Department of Pediatrics,; Yale Cancer Center.

Abstract

Heterogeneity of tumor cells and their microenvironment can affect outcome in cancer. Blockade of immune checkpoints (ICPs) expressed only on a subset of immune cells leads to durable responses in advanced melanoma. Tissue-resident memory T (TRM) cells have recently emerged as a distinct subset of memory T cells in nonlymphoid tissues. Here, we show that functional properties and expression of ICPs within tumor-infiltrating lymphocytes (TILs) differ from those of blood T cells. TILs secrete less IL-2, IFN-γ, and TNF-α compared with circulating counterparts, and expression of VEGF correlated with reduced TIL infiltration. Within tumors, ICPs are particularly enriched within T cells with phenotype and genomic features of TRM cells and the CD16+ subset of myeloid cells. Concurrent T cell receptor (TCR) and tumor exome sequencing of individual metastases in the same patient revealed that interlesional diversity of TCRs exceeded differences in mutation/neoantigen load in tumor cells. These findings suggest that the TRM subset of TILs may be the major target of ICP blockade and illustrate interlesional diversity of tissue-resident TCRs within individual metastases, which did not equilibrate between metastases and may differentially affect the outcome of immune therapy at each site.

Conflict of interest statement

The authors have declared that no conflict of interest exists.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center